KMT2A and leukemia: Moreover, treatment of patient-derived xenograft (PDX) models of MLL-rearranged leukemia with 75 mg/kg twice daily of both compounds resulted in a significant reduction of leukemia burden in bone marrow, spleen, and peripheral blood after 4 weeks, accompanied by a parallel good tolerance profile (Perner et al., 2020).